Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001999371-25-005875
Filing Date
2025-05-12
Accepted
2025-05-12 16:35:45
Documents
82
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT tnxp-10q_033125.htm   iXBRL 10-Q 874365
2 SECTION 302 CERTIFICATION ex31-01.htm EX-31.01 10774
3 SECTION 302 CERTIFICATION ex31-02.htm EX-31.02 10895
4 SECTION 906 CERTIFICATION ex32-01.htm EX-32.01 5566
  Complete submission text file 0001999371-25-005875.txt   6008474

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tnxp-20250331.xsd EX-101.SCH 55713
6 XBRL CALCULATION FILE tnxp-20250331_cal.xml EX-101.CAL 71590
7 XBRL DEFINITION FILE tnxp-20250331_def.xml EX-101.DEF 202962
8 XBRL LABEL FILE tnxp-20250331_lab.xml EX-101.LAB 415604
9 XBRL PRESENTATION FILE tnxp-20250331_pre.xml EX-101.PRE 329685
85 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-10q_033125_htm.xml XML 770398
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36019 | Film No.: 25935450
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)